Update on CryoLife Developments

Frequently Asked Questions For Medafor Shareholders About CryoLife’s Unsolicited Proposal MINNEAPOLIS, February 24, 2010

Shareholder Communication - Response to CryoLife’s Unsolicited Proposal. MINNEAPOLIS, February 10, 2010

Bruising Biologics Battle Erupts Orthopedics This Week, January 26, 2010

Shareholder Communication-Initial Response to CryoLife’s Unsolicited Proposal. MINNEAPOLIS, January 25, 2010

New Communication from Medafor – Update of CryoLife Litigation and Recent Developments. MINNEAPOLIS, January 15, 2010.

Shareholder Communication - Summary of CryoLife Litigation.
MINNEAPOLIS, November 23, 2009

---

HOME | ABOUT MEDAFOR | PRODUCTS | TECHNOLOGY | RESEARCH | MEDIA CENTER | CONTACT US

Medafor, Inc., was founded in 1999 to develop and market applications for its patented MPH® (Microporous Polysaccharide Hemospheres Technology). Statements presented on this page have not been evaluated by the U.S. FDA. See respective Instructions for Use for product applications and indications. Site content and images Copyright 2007 Medafor, Inc. All Rights Reserved. No part of this site may be copied, republished, excerpted or transferred to other media without the express written consent of Medafor, Inc. Arista™AH, MPH®, Medafor®, MPatcH®, FlexiTip™ are trademarks of Medafor, Inc. Other trademarks mentioned are the property of their respective companies. For information, contact Medafor at 1-763-571-6300.